0001564590-20-058068.txt : 20201222 0001564590-20-058068.hdr.sgml : 20201222 20201222171339 ACCESSION NUMBER: 0001564590-20-058068 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20201218 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201222 DATE AS OF CHANGE: 20201222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Allakos Inc. CENTRAL INDEX KEY: 0001564824 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454798831 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38582 FILM NUMBER: 201408937 BUSINESS ADDRESS: STREET 1: 975 ISLAND DRIVE STREET 2: SUITE 201 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-597-5002 MAIL ADDRESS: STREET 1: 975 ISLAND DRIVE STREET 2: SUITE 201 CITY: REDWOOD CITY STATE: CA ZIP: 94065 8-K 1 allk-8k_20201218.htm 8-K allk-8k_20201218.htm
false 0001564824 0001564824 2020-12-18 2020-12-18

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

December 18, 2020

 

Allakos Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

 

Delaware

 

001-38582

 

45-4798831

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer
Identification No.)

 

 

 

 

 

975 Island Drive, Suite 201

Redwood City, California 94065

(Address of principal executive offices, including zip code)

(650597-5002

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, par value $0.001

ALLK

The Nasdaq Global Select Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 

 


 

 

Item 1.01 Entry into a Material Definitive Agreement.

On December 18, 2020, Allakos Inc. (the “Company”) entered into an additional ten-year commercial supply agreement (the “Supply Agreement”) with Lonza Sales AG (“Lonza”), pursuant to which Lonza has agreed to manufacture lirentelimab (AK002) for the Company, among other related services. Lonza is currently the Company’s sole manufacturer for lirentelimab (AK002).

Pursuant to the Supply Agreement, the Company will provide rolling forecasts to Lonza that reflect future manufacturing of lirentelimab (AK002) by Lonza.

The Supply Agreement may be terminated by either party before its expiration in the event of certain breaches of the Supply Agreement by the other party. In addition, the Company may terminate the Supply Agreement under other specified conditions.

The Supply Agreement includes customary indemnification, intellectual property protection, remedies and confidentiality terms, as well as certain quality requirements.  

The foregoing summary of the Supply Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Supply Agreement, a copy of which the Company anticipates filing as an exhibit to the Company’s Annual Report on Form 10-K for the period ending December 31, 2020.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information included in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 2.03 of this Current Report on Form 8-K by reference.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 21, 2020, the Board of Directors (the “Board”) of Allakos Inc. (the Company”), upon the recommendation of the Corporate Governance and Nominating Committee of the Board, increased the size of the Board to seven members and appointed Natalie Holles to the Board to fill the newly created directorship, effective immediately. Ms. Holles will serve as a Class II director of the Company, to hold office until the Company’s 2023 annual meeting of stockholders and until her successor is elected and qualified, or until her earlier death, resignation or removal. The Board has determined that Ms. Holles satisfies the applicable independence requirements of the Nasdaq Listing Rules.

Following the date of her appointment to the Board, Ms. Holles shall receive options to purchase 15,400 shares of the Company’s common stock pursuant to the Company’s 2018 Equity Incentive Plan. One thirty-sixth of the shares subject to the options shall vest each month following the commencement of Ms. Holles’s service, subject to her continued service to the Company on each such vesting date.

Ms. Holles will participate in the Company’s Outside Director Compensation Policy, which was amended and restated as of April 1, 2020. Under the policy, non-employee directors receive an annual cash retainer of $47,500 (plus additional amounts for committee service, if appointed), an initial grant of a stock option upon joining the Board (described above), and an annual stock option covering 7,700 shares of common stock.

Additionally, the Company and Ms. Holles have entered into an indemnification agreement in substantially the same form that the Company has entered into with each of its existing directors.

On December 22, 2020, the Company issued a press release to announce the appointment of Ms. Holles to the Board, A copy of the press release issued concerning the appointment is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

 

Description

 

 

 

99.1

 

Press Release dated December 22, 2020.

 

 

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Allakos Inc.

 

 

 

 

Date: December 22, 2020

 

By:

/s/ Robert Alexander

 

 

 

Robert Alexander

 

 

 

Chief Executive Officer

 

2

EX-99.1 2 allk-ex991_8.htm EX-99.1 allk-ex991_8.htm

Exhibit 99.1

 

Allakos Appoints Natalie Holles to its Board of Directors

 

REDWOOD CITY, Calif., December 22, 2020 – Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced the appointment of Natalie Holles, president and chief executive officer of Audentes Therapeutics, to the Allakos board of directors.

 

“Natalie’s extensive background in company-building and commercial readiness makes her an exceptional addition to our board and will provide valuable insights as we continue to advance late-stage clinical trials of lirentelimab and begin laying the foundation for its potential commercialization,“ said Robert Alexander, PhD, chief executive officer of Allakos.“

 

Ms. Holles has contributed to the leadership and success of several biotechnology companies. She has more than two decades of experience in senior-level leadership, business development, corporate strategy and commercial operations across a range of therapeutic areas. Ms. Holles is currently the President and Chief Executive Officer of Audentes Therapeutics (acquired by Astellas Pharma in 2020) which she joined in 2015 as Chief Operating Officer. Prior to joining Audentes, Ms. Holles served as senior vice president, corporate development at Hyperion Therapeutics (acquired by Horizon Pharma in 2015). Earlier in her career, Ms. Holles served as vice president, business development at KAI Pharmaceuticals (acquired by Amgen in 2012) and also held corporate development and commercial roles at InterMune (acquired by Roche in 2014).

 

Ms. Holles is a member of the Board of Directors for Rubius Therapeutics. She holds an M.A. in molecular, cellular and developmental biology from the University of Colorado, Boulder, where she was a Howard Hughes Medical Institute predoctoral fellow, and an A.B. in human biology from Stanford University.

 

“I am honored to join the Allakos Board of Directors, and I share the company’s vision of developing innovative therapies that transform patients’ lives,” said Ms Holles. “I look forward to working with existing board members and the Allakos management team to support their goal of developing and commercializing a unique treatment for people with eosinophilic gastrointestinal diseases.”

About Allakos

Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, lirentelimab (AK002), is being evaluated in a Phase 3 study in eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD) and a Phase 2/3 study in eosinophilic esophagitis (EoE). Lirentelimab targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils. Inappropriately activated eosinophils and mast cells have been identified as key drivers in a number of severe diseases affecting the gastrointestinal tract, eyes, skin, lungs and other organs. Lirentelimab has been tested in multiple clinical studies. In these studies, lirentelimab eliminated blood and tissue eosinophils, inhibited mast cells and improved disease symptoms in patients with EG and/or EoD, EoE, mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria and indolent systemic mastocytosis. For more information, please visit the Company's website at www.allakos.com.

 

 

###

 


 

Source: Allakos Inc.

 

Investor Contact:

 

Media Contact:

Adam Tomasi, President, COO and CFO

 

Denise Powell

ir@allakos.com

 

denise@redhousecomms.com

 

 

GRAPHIC 3 gu1splvgd4sm000001.jpg GRAPHIC begin 644 gu1splvgd4sm000001.jpg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allk-20201218.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document And Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 allk-20201218_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Entity Registrant Name Entity Registrant Name Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Document Period End Date Document Period End Date Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of Each Class Security12b Title Trading Symbol Trading Symbol Name of Each Exchange on Which Registered Security Exchange Name EX-101.PRE 6 allk-20201218_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 allk-8k_20201218_htm.xml IDEA: XBRL DOCUMENT 0001564824 2020-12-18 2020-12-18 false 0001564824 8-K 2020-12-18 Allakos Inc. DE 001-38582 45-4798831 975 Island Drive Suite 201 Redwood City CA 94065 650 597-5002 Common Stock, par value $0.001 ALLK NASDAQ false false false false false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Document And Entity Information
Dec. 18, 2020
Cover [Abstract]  
Entity Registrant Name Allakos Inc.
Document Type 8-K
Amendment Flag false
Entity Central Index Key 0001564824
Document Period End Date Dec. 18, 2020
Entity Emerging Growth Company false
Entity File Number 001-38582
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 45-4798831
Entity Address, Address Line One 975 Island Drive
Entity Address, Address Line Two Suite 201
Entity Address, City or Town Redwood City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94065
City Area Code 650
Local Phone Number 597-5002
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of Each Class Common Stock, par value $0.001
Trading Symbol ALLK
Name of Each Exchange on Which Registered NASDAQ
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports allk-8k_20201218.htm allk-20201218.xsd allk-20201218_lab.xml allk-20201218_pre.xml allk-ex991_8.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "allk-8k_20201218.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "allk-8k_20201218.htm" ] }, "labelLink": { "local": [ "allk-20201218_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "allk-20201218_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "allk-20201218.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "allk", "nsuri": "http://www.allakos.com/20201218", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "allk-8k_20201218.htm", "contextRef": "C_0001564824_20201218_20201218", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "role": "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "allk-8k_20201218.htm", "contextRef": "C_0001564824_20201218_20201218", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "verboseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of Each Class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of Each Exchange on Which Registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.allakos.com/20201218/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001564590-20-058068-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-058068-xbrl.zip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end